Lipella pharmaceuticals announces successful top line results of phase 2a clinical trial of lp-10

Results to be presented at biotech showcasetm 2023 on wednesday, january 11 th at 2:00pm pst pittsburgh , jan. 11, 2023 /prnewswire/ -- lipella pharmaceuticals inc. (nasdaq: "lipo") ("lipella," "our, "us" or the "company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced top line results of the company's recently completed phase 2a clinical trial evaluating the safety and efficacy of its drug candidate lp-10 for hemorrhagic cystitis, a rare but highly morbid disease for which there are currently no fda approved treatments. jonathan kaufman, chief executive officer, will present a corporate overview including the top-line results, at biotech showcase 2023™ on wednesday, january 11th at 2:00pm pst at the hilton san francisco - union square, 333 o'farrell street, san francisco, ca.
LIPO Ratings Summary
LIPO Quant Ranking